Tears for Life

Dornier Medtech America is a medical device company. It had developed the Medilas D Family Lasers, Including Medilas D Litebeam, Litebeam +, Urobeam, Multibeam, Flexipulse And Magnapulse.Dornier MedTech develops, manufacturers, markets and services lithotripters, orthopedic shock wave devices, urotables and medical aesthetic lasers worldwide, providing innovative therapeutic, diagnostic and service solutions for numerous healthcare fields. Dornier MedTech invented extracorporeal shockwave lithotripsy, (ESWL), more than 25 years ago for the disintegration of kidney stones, which is today the gold standard for urinary stone treatment.

Windy Hill Medical is a medical device and pharmaceutical company focused on the development of products to reduce the risk of developing breast cancer in patients deemed to be at high risk.

Lifepoint is a medical technology company developing rapid and cost effective, non-invasive, on-site diagnostic products. The Company has developed and will continue to develop patented, proprietary technologies utilizing saliva as a test specimen to provide blood equivalent diagnostic results without the need for blood or urine.

Biopticon Corporation is aimed to develop medical diagnostic devices using laser, photonics and image processing based technologies.

BioHorizons is a dental implant and biologics company that operates in the healthcare industry. The company offers a range of products including dental implants, surgical planning software, and tissue regeneration solutions designed to replace missing teeth. It primarily serves the dental healthcare sector. It was founded in 1994 and is based in Birmingham, Alabama.

PreMD Inc. is dedicated to saving and improving people's lives with simple, painless and patient-friendly tests that can detect life-threatening illnesses at a. The company's tests do not require any patient preparation or dietary restrictions and can be performed at the point of care, in a laboratory setting and, in some cases, even at home. The company's cardiovascular risk assessment technology, PREVU* Skin Sterol Test, assesses a patient's risk of heart disease by non-invasively measuring the amount of cholesterol in the skin tissues. PreMD's non- or minimally-invasive tests for early-stage colorectal, lung and breast cancers detect a cancer-associated sugar in a sample of rectal mucus, sputum and breast nipple aspirate fluid, respectively. The company's cancer tests are in development.